Biological material pre-fixation treatment

• US 5,720,777 A
• Filed: 05/16/1995
• Issued: 02/24/1998
• Est. Priority Date: 04/18/1994
• Status: Expired due to Term

• Current Assignee: Hancock Jaffe Laboratories, Inc.
• Original Assignee: Hancock Jaffe Laboratories, Inc.
• Inventors: Jaffe, Norman, Hancock, Warren D.
• Primary Examiner(s): Willse, David H.
• Application Number:
  US08/442,017
• Time in Patent Office: 1,015 Days
• Field of Search: 623/2, 623/900
• US Class Current: 623/2.13
• CPC Class Codes: A61L 2430/20 for reconstruction of the heart, e.g. heart valves
• CPC Class Codes: A61L 27/3604 characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
• CPC Class Codes: A61L 27/3645 Connective tissue
• CPC Class Codes: A61L 27/3683 subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
• CPC Class Codes: A61L 27/3687 characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
• CPC Class Codes: A61L 27/3691 characterised by physical conditions of the treatment, e.g. applying a compressive force to the composition, pressure cycles, ultrasonic/sonication or microwave treatment, lyophilisation
• CPC Class Codes: A61L 27/507 for artificial blood vessels apparatus for applying cells on a blood vessel prosthesis A61F2/062
• CPC Class Codes: Y10S 623/901 Method of manufacturing prosthetic device
• CPC Class Codes: Y10S 623/915 Method or apparatus for preparing biological material

Abstract

Disclosed is a controlled autolysis method for making biological tissue substantially acellular by exposing the biological material, prior to any fixation thereof, to at least one buffered solution having a pH in the range from about 5.0 to 8.0 and a temperature in the range from about 12° C. to 30° C. for a sufficient period of time to render at least one region of the biological material substantially acellular while substantially preserving the structural integrity and non-cellular structural components of the biological material. Also disclosed is a method of making a bioprosthetic heart valve using biological material that has been treated by controlled autolysis and a method of treating a mammal having a defective heart valve using a bioprosthetic heart valve made, in part, by controlled autolysis.

Claims

1. A bioprosthetic heart valve, comprising:

at least one leaflet that is adapted for reciprocal motion from an open position to a closed position upon blood flow through the valve;

the at least one leaflet being formed, at least in part, of biological material that has been subjected to controlled autolysis, wherein the biological material that is subjected to controlled autolysis has structural integrity and comprises cells and non-cellular structural components, and wherein the controlled autolysis comprises exposing the biological material, prior to any fixation thereof, to at least one buffered solution having a pH in the range from about 5.0 to 8.0 and a temperature in the range from about 12°

C. to 30°

C. for a sufficient period of time to facilitate degradation of cells by autolytic enzymes within the cells so as to render at least one region of the biological material substantially acellular while substantially preserving the structural integrity and non-cellular structural components of the biological material.

2. The bioprosthetic heart valve of claim 1, wherein the bioprosthetic valve additionally comprises a generally tubular stent having an inflow end and an outflow end, and wherein the at least one leaflet is positioned in relation to the stent such that the reciprocal motion of the at least one leaflet occurs as blood flows from the inflow end of the stent through the outflow end of the stent.

3. The bioprosthetic heart valve of claim 2, wherein the stent has a generally circular cross-section.

4. The bioprosthetic heart valve of claim 2, wherein the stent has an inner surface and an outer surface and wherein the at least one leaflet is attached to the inner surface.

5. The bioprosthetic heart valve of claim 2, wherein the stent comprises non-biological material.

6. The bioprosthetic heart valve of claim 1, wherein the at least one region of the biological material that is rendered substantially acellular is substantially all of the leaflet.

7. The bioprosthetic heart valve of claim 1, wherein the biological material is porcine.

8. The bioprosthetic heart valve of claim 7, wherein the biological material is a leaflet of a heart valve or a fragment of a leaflet of a heart valve.

9. The bioprosthetic heart valve of claim 1, wherein the biological material is a heart valve or a fragment of a heart valve.

10. The bioprosthetic heart valve of claim 1, wherein the controlled autolysis additionally comprises the step of fixing the biological material after the exposing step.

11. The bioprosthetic heart valve of claim 1, wherein the biological material is derived from at least one animal selected from the group consisting of a bovine, a porcine, an ovine, a Macropodidae, a non-human primate, a human and a combination of any of the foregoing.

12. The bioprosthetic heart valve of claim 1, wherein the biological material is at least one material selected from the group consisting of diaphragm, pericardium, heart valve, umbilical cord, artery, vein, fascia lata, dura mater, tendon, ligament, tympanic membrane, a fragment of any of the foregoing, and a combination of any of the foregoing.

13. The bioprosthetic heart valve of claim 1, wherein the non-cellular structural components include at least one structural component selected from the group consisting of collagen, elastin, laminin, teninsin, actinin, proteoglycans, a fragment of any of the foregoing, and a combination of any of the foregoing.

14. A bioprosthetic heart valve, comprising:

at least one leaflet that is adapted for reciprocal motion from an open position to a closed position upon blood flow through the valve;

the at least one leaflet being formed, at least in part, of biological material that has been subjected to controlled autolysis, wherein the biological material that is subjected to controlled autolysis has structural integrity and comprises cells and non-cellular structural components, and wherein the controlled autolysis consists essentially of exposing the biological material, prior to any fixation thereof, to at least one solution consisting essentially of a buffer having a pH in the range from about 5.0 to 8.0 and a temperature in the range from about 12°

C. to 30°

C. for a sufficient period of time to facilitate degradation of cells by autolytic enzymes within the cells so as to render at least one region of the biological material substantially acellular while substantially preserving the structural integrity and non-cellular structural components of the biological material.